Skip to main content

Table 1 Anti-proliferative activity of TAE226 against cancer cell lines

From: Pharmacological profiling of a dual FAK/IGF-1R kinase inhibitor TAE226 in cellular and in vivo tumor models

Cell origin

Cell line name

GI50 (μM)

n

Breast

MCF-7

1.2 ± 0.22

7

MCF-7/ADR-RES

1.1 ± 0.23

4

MDA-MB-231

0.56 ± 0.22

3

MDA-MB-435

1.6 ± 0.044

3

MDA-MB-453

1.5 ± 0.32

3

4T1

0.16 ± 0.022

5

MTF7

1.4 ± 0.26

3

Prostate

DU145

0.23 (0.20, 0.25)

2

PC-3/M

0.83 ± 0.29

4

Lung

NCI-H23

0.29 (0.24, 0.35)

2

NCI-H460

0.40 ± 0.028

4

LLC

0.13 ± 0.0077

4

Colon

COLO205

0.21 (0.11, 0.30)

2

HCT-15

0.71 ± 0.1

5

HCT-116

0.42 ± 0.056

3

SW620

0.51 ± 0.024

3

WiDr

0.14 ± 0.030

5

Stomach

KATOIII

0.54 ± 0.064

3

Pancreas

BxPC-3

0.53 ± 0.11

3

MIA PaCa-2

0.26 ± 0.062

4

PANC-1

3.6 ± 0.93

3

SUIT-2

0.18 ± 0.029

3

Glioma

A172

1.6 (2.2, 1.1)

2

DBTRG-05MG

0.47 ± 0.054

3

LN-18

0.96 ± 0.12

3

LN-229

0.56 ± 0.043

3

T98G

0.42 (0.21, 0.63)

2

U-87 MG

1.0 (1.1, 0.97)

2

U-118 MG

1.3 (0.69, 1.8)

2

U-373 MG

1.4 (0.72, 2.0)

2

Melanoma

A375M

0.29 (0.15, 0.43)

2

C32

1.8 ± 0.31

3

C8161

0.90 (0.68, 1.1)

2

SK-MEL-23

0.17 ± 0.0090

3

SK-MEL-93

0.25 ± 0.050

4

WM1158

0.33 ± 0.099

3

Myeloma

RPMI8226

0.33 ± 0.060

3

  1. TAE226 concentrations causing 50% inhibition of net cell growth (GI50) are given. Results are expressed as mean ± SEM (except experiments with n = 2 where 2 individual values are included). Cell growth was assessed by sulforhodamine B staining for adhesive cell lines and by AlamarBlue for suspension cell lines. GI50 values were calculated after 48 h treatment with TAE226
Back to article page

BMC Research Notes

ISSN: 1756-0500

Contact us